Guoguang Ying

Title: Guoguang Ying: Innovator in Synthetic Peptides and Cancer Treatment

Introduction

Guoguang Ying is a prominent inventor based in Tianjin, China. He has made significant contributions to the field of biotechnology, particularly in the development of synthetic peptides and cancer treatment methodologies. With a total of 3 patents, his work has the potential to impact medical diagnostics and therapeutic strategies.

Latest Patents

Ying's latest patents include a synthetic peptide with an amino acid sequence SEQ ID NO: 1, which features a cysteine at its N-terminal. This invention also encompasses an artificial antigen and an antibody specific to the human EHD2 protein. The patent outlines a method for preparing this antibody, which is applicable in immunohistochemical methods for EHD2 detection, as well as in cancer diagnosis and prognosis. Another notable patent involves a method and pharmaceutical composition for inhibiting the PI3K/AKT/mTOR signaling pathway. This method is designed for treating patients with diseases such as cancer, hamartoma syndrome, and hereditary myopathy, utilizing a dual antagonist pyridine compound.

Career Highlights

Throughout his career, Guoguang Ying has worked with various organizations, including Targeted Therapeutics, LLC and Tianjin Yingshibo Technology Development Co., Ltd. His experience in these companies has allowed him to refine his expertise in biotechnology and therapeutic development.

Collaborations

Ying has collaborated with notable professionals in his field, including Lei Duan and Victor Levenson. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Guoguang Ying's innovative work in synthetic peptides and cancer treatment exemplifies the potential of biotechnology to transform medical practices. His contributions are paving the way for new diagnostic and therapeutic options in the fight against cancer and other diseases.